Bispecific TfR1/Target Antibody Shuttles (e.g. Anti-Aβ Trontinemab): Latest Preclinical & Clinical Insights
9:30 am - Wednesday 2nd December 2026
- Assess how bispecific constructs couple transport and therapeutic domains to enable BBB crossing while maintaining target engagement in the brain parenchyma
- Evaluate dose-dependent saturation of TfR1 transport pathways and its effect on nonlinear brain uptake
- Characterize intrabrain distribution patterns (capillary-associated vs parenchymal delivery) to assess true tissue penetration versus vascular trapping
- Compare clinical biomarker strategies (e.g. PET imaging, CSF biomarkers) for demonstrating CNS target engagement
